

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII – Pharmacists

Chapter 5 – Pharmacists

§523. Collaborative Drug Therapy Management

- A. Definitions. As used in this Chapter, the following terms shall have the meaning ascribed to them in this Section:

Board – the Louisiana Board of Pharmacy.

Collaborative Drug Therapy Management or *Drug Therapy Management* – that practice in which a pharmacist, ~~to the extent authorized by a collaborative drug therapy management agreement,~~ voluntarily agrees with a physician ~~registered with the Louisiana State Board of Medical Examiners,~~ to manage the disease specific drug therapy of one or more patients of such physician, within a predetermined range of medication selected by the physician and set forth in a patient specific written ~~protocol or order set.~~ Drug therapy management shall be limited to:

- a. monitoring and modifying a disease specific drug therapy;
- b. collecting and reviewing patient history;
- c. obtaining and reviewing vital signs, including pulse, temperature, blood pressure, and respiration;
- d. ordering, evaluating, and applying the results of laboratory tests directly related to the disease specific drug therapy being managed under ~~written protocol~~ an order set, provided such tests do not require the pharmacist to interpret such testing or formulate a diagnosis;
- e. ~~administration of vaccines to a patient 16 years of age or older by a pharmacist authorized to administer vaccines by the board;~~
- f. ~~providing up to a single seven day supply of a single drug after all refills authorized on the original prescription issued to the patient by the patient's physician have been dispensed; and~~
- g. providing disease or condition specific patient education and counseling.

~~*Collaborative Drug Therapy Management Agreement* – a written document in which a pharmacist and a physician identify the terms and conditions under which they voluntarily agree to participate in collaborative drug therapy management.~~

Controlled Substance – any substance defined, enumerated, or included in federal or state statute or regulations, or any substance which may hereafter be designated as a controlled substance by amendment or supplementation of such statute or regulations.

Disease Specific Drug Therapy – a specific drug or drugs prescribed by a physician for a specific patient of such physician that is generally accepted within the standard of care for treatment of ~~one of~~ the following diseases or conditions:

- a. ~~treatment and prevention of arterial and venous clot propagation and disease, i.e., anti-coagulant therapy;~~
- b. ~~treatment and prevention of diabetes;~~
- e. ~~adjustment of medication administered by inhalant for treatment of asthma;~~
- d. ~~treatment and prevention of dyslipidemia;~~
- e. ~~smoking cessation therapy;~~
- f. ~~administration of disease specific vaccines to patients 16 years of age or older; and~~
- g. ~~such other drugs, diseases or conditions as may be subsequently recommended by the advisory committee and approved by the board.~~

Drug – (a) any substance recognized as a drug in the official compendium, or supplement thereto, designated by the board for use in the diagnosis, cure, mitigation, treatment or prevention of diseases in humans or animals; (b) any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of diseases in humans or other animals, or (c) any substance other than food intended to affect the structure or any function of the body of humans or other animals.

55 *Drugs of Concern* – a drug that is not a controlled substance but which is nevertheless defined and
 56 identified in accordance with procedures established by the Louisiana Prescription Monitoring
 57 Program Act, R.S. 40:1001-1014, as a drug with the potential for abuse.

58 *Pharmacist* – for purposes of this Section, an individual currently licensed by the board who has a
 59 current unrestricted license to engage in the practice of pharmacy in the this state duly licensed by the
 60 board, who is approved by the board to engage in collaborative practice for a specific disease or
 61 condition based on the pharmacist's training and experience.

62 *Physician* – an individual lawfully entitled to engage in the practice of medicine in this state as
 63 evidenced by a current, unrestricted license duly issued by the Louisiana State Board of Medical
 64 Examiners.

65 *Prescribe* – a request or order transmitted in writing, orally, electronically or by other means of
 66 telecommunication for a drug that is issued in good faith, in the usual course of professional practice
 67 and for a legitimate medical purpose, by a physician for the purpose of correcting a physical, mental or
 68 bodily ailment of his patient.

69 *Written Protocol Order Set* – a written set of directives or instructions containing each of the
 70 components specified elsewhere in this Section for collaborative drug therapy management of disease
 71 specific drug therapy for a specific patient. The ~~written protocol~~ order set shall be signed by the
 72 physician and represents the physician orders for the collaborative drug therapy management to be
 73 provided to the patient.

74 B. Registration

75 1. Eligibility

- 76 a. No pharmacist shall engage in collaborative drug therapy management in this state
 77 until registered with the board in accordance with this Section. To be eligible for
 78 registration, a pharmacist shall, as of the date of the application:
- 79 i. possess a current, unrestricted license to practice pharmacy issued by the
 80 board and not be the subject of a pending investigation or complaint by the
 81 board or by the pharmacy licensing authority of any other state or
 82 jurisdiction;
 - 83 ii. be actively engaged in the practice of pharmacy in this state and the
 84 provision of pharmacist care similar to the activities anticipated in the
 85 collaborative drug therapy management agreement.
- 86 b. A pharmacist shall be deemed ineligible for registration of collaborative drug
 87 therapy management who:
- 88 i. does not possess the qualifications prescribed by §523.B.1.a;
 - 89 ii. has voluntarily surrendered or had suspended, revoked, or restricted his
 90 controlled dangerous substances license, permit, or registration (state or
 91 federal);
 - 92 iii. has had a pharmacy license suspended, revoked, placed on probation or
 93 restricted in any manner by the board or by the pharmacy licensing
 94 authority of any other state or jurisdiction;
 - 95 iv. has had an application for pharmacist licensure rejected or denied; or
 - 96 v. has been, or is currently in the process of being denied, terminated,
 97 suspended, refused, limited, placed on probation or under other
 98 disciplinary action with respect to participation in any private, state, or
 99 federal health insurance program.
- 100 c. The board may, in its discretion, waive the limitations referenced in Subparagraph
 101 B.1.b of this Section on a case-by-case basis.
- 102 d. The board may deny registration to an otherwise eligible pharmacist for any of the
 103 causes enumerated in R.S. 37:1241.A, or any other violation of the provisions of
 104 the Pharmacy Practice Act or the board's rules.
- 105 e. The burden of satisfying the board as to the eligibility of a pharmacist for
 106 registration to engage in collaborative drug therapy management shall be upon the
 107 pharmacist. A pharmacist shall not be deemed to possess such qualifications
 108 unless and until the pharmacist demonstrates and evidences such qualifications in
 109 the manner prescribed by and to the satisfaction of the board.
 110
 111

- 112 2. Application and Issuance
- 113 a. Application for registration to engage in collaborative drug therapy management
- 114 shall be made upon forms supplied by the board. Application forms and
- 115 instructions may be obtained from the board's website at www.labp.com or by
- 116 contacting the board's office.
- 117 b. An application for registration to engage in collaborative drug therapy
- 118 management shall include:
- 119 i. the pharmacist's full name, license number, mailing address of record,
- 120 and emergency contact information;
- 121 ii. the nature of the collaborative drug therapy management activities
- 122 contemplated, i.e., the disease or condition proposed for management;
- 123 iii. a description of the pharmacist's professional education that qualifies him
- 124 to engage in collaborative drug therapy management activities described
- 125 in the agreement application;
- 126 iv. proof documented in a form satisfactory to the board that the pharmacist
- 127 possesses the qualifications set forth in this Section;
- 128 v. ~~a fully executed copy of a collaborative drug therapy management~~
- 129 ~~agreement conforming to the requirements of this Section;~~
- 130 vi. ~~confirmation the pharmacist shall only engage in collaborative drug~~
- 131 ~~therapy management to the extent detailed in the agreement and in~~
- 132 ~~accordance with the rules of the board; and~~
- 133 vii. such other information and documentation as the board may require to
- 134 evidence qualification for registration.
- 135 c. The board may reject or refuse to consider any application for registration which is
- 136 not complete in every detail required by the board ~~or may refuse to consider a~~
- 137 ~~collaborative drug therapy management agreement which fails to comply with the~~
- 138 ~~minimum requirements of this Section.~~ The board may, in its discretion, require a
- 139 more detailed or complete response to any request for information set forth in the
- 140 application as a condition to consideration.
- 141 d. A pharmacist seeking registration to engage in collaborative drug therapy
- 142 management shall be required to appear before the board or its designee if the
- 143 board has questions concerning the nature or scope of the pharmacist's application,
- 144 finds discrepancies in the application, or for other good cause as determined by the
- 145 board.
- 146 e. When all the qualifications, requirements, and procedures of this Section are met
- 147 to the satisfaction of the board, the board shall approve and register a pharmacist to
- 148 engage in collaborative drug therapy management. Registration of authority to
- 149 engage in collaborative drug therapy management shall not be effective until the
- 150 pharmacist receives notification of approval from the board.
- 151 f. Although a pharmacist shall notify the board each time he intends to engage in
- 152 collaborative drug therapy management with a physician other than the physician
- 153 identified in the pharmacist's original application, registration with the board is
- 154 only required once. The board shall maintain a list of pharmacists who are
- 155 registered to engage in collaborative drug therapy management.
- 156 g. Each pharmacist registered to engage in collaborative drug therapy management
- 157 shall be responsible for updating the board within 10 days in the event of any
- 158 change in the information recorded in the original application.
- 159 3. Expiration of Registration; Renewal
- 160 a. A pharmacist's registration to engage in collaborative drug therapy management
- 161 with a physician shall terminate and become void, null and without effect upon the
- 162 earlier of:
- 163 i. death of either the pharmacist or physician;
- 164 ii. loss of license of ~~either the pharmacist or physician~~;
- 165 iii. disciplinary action limiting the ability of ~~either the pharmacist or the~~
- 166 ~~physician~~ to enter into collaborative drug therapy management;
- 167 iv. notification to the board that ~~either the pharmacist or physician~~ has
- 168 withdrawn from collaborative drug therapy management;

- 169 v. a finding by the board of any of the causes that would render a pharmacist
 170 ineligible for registration; or
 171 vi. expiration of a pharmacist's license or registration to engage in
 172 collaborative drug therapy management for failure to timely renew such
 173 license or registration.
- 174 b. Registration of authority to engage in collaborative drug therapy management shall
 175 expire annually on the same day as a pharmacist's license unless renewed by the
 176 pharmacist by ~~submitting an application to the board upon forms supplied by the~~
 177 ~~board, together with verification of the accuracy of registration and collaborative~~
 178 ~~drug therapy management agreement information on file with the board~~
 179 completing the application form supplied by the board. An application for
 180 registration renewal shall be made part of and/or accompany a pharmacist's
 181 renewal application for pharmacist licensure.
- 182 c. The timely submission of an application for renewal of registration shall operate to
 183 continue the expiring registration in effect pending renewal of registration or other
 184 final action by the board on such application for renewal.
- 185 C. Advisory Committee. The Collaborative Drug Therapy Management Advisory Committee, constituted
 186 as provided for in LAC 46:XLV.7417, shall assist the Board of Medical Examiners and the Board of
 187 Pharmacy on matters relative to collaborative drug therapy management. The President of the Board
 188 of Pharmacy shall appoint a pharmacist to serve on the committee, and said pharmacist shall serve at
 189 the pleasure of the Board of Pharmacy.
- 190 D. Standards of Practice
- 191 1. Authority, Responsibility, and Limitations of Collaborative Drug Therapy Management
- 192 a. A pharmacist registered with the board under this Section may engage in
 193 collaborative drug therapy management with a physician:
 194 i. ~~to the extent authorized by a collaborative drug therapy management~~
 195 ~~agreement filed with and approved by the board; and~~
 196 ii. in accordance with a patient specific, drug specific, disease specific
 197 ~~written protocol order set~~, satisfying the requirements of this Section.
- 198 b. A pharmacist engaged in collaborative drug therapy management shall:
 199 i. retain professional responsibility to his patient for the management of ~~his~~
 200 their drug therapy;
 201 ii. establish and maintain a pharmacist-patient relationship with each patient
 202 subject to ~~the~~ collaborative drug therapy management ~~agreement~~;
 203 iii. be geographically located to be physically present to provide pharmacist
 204 care to a patient subject to collaborative drug therapy management;
 205 iv. provide on a scheduled ~~defined in the written protocol~~ basis no less than
 206 every three months, a ~~periodic~~ status report on the patient, including but
 207 not limited to, any problem, complication, or other issues relating to
 208 patient non-compliance with drug therapy management. This
 209 requirement may be met by entering the information in the patient's
 210 medical record.; and
 211 v. be available through direct telecommunication for consultation,
 212 assistance, and direction.
- 213 c. A pharmacist's registration to engage in collaborative drug therapy management
 214 with a physician is personal to the pharmacist. A ~~registered~~ pharmacist registered
 215 to engage in drug therapy management shall not allow another pharmacist not so
 216 registered or any other individual to exercise the authority conferred by such
 217 registration. ~~A registered pharmacist shall not engage in collaborative drug~~
 218 ~~therapy management with a non-physician or with any physician who is not a party~~
 219 ~~to the pharmacist's collaborative drug therapy management agreement on file with~~
 220 ~~the board.~~
- 221 d. Collaborative drug therapy management shall only be utilized for ~~those conditions~~
 222 ~~or diseases identified in, and in the manner specified by, this Section.~~ Additional
 223 conditions or diseases for which there are generally accepted standards of care for
 224 disease specific drug therapy may be identified by the advisory committee and
 225 approved by the board. ~~disease specific drug therapy as defined in this Section.~~

- 226 e. Only a pharmacist who holds the academic degree of Doctor of Pharmacy, which
 227 degree provided specific training in the area of anti-coagulant drug therapy, shall
 228 engage in collaborative drug therapy management in such particular area of
 229 practice covered by a collaborative drug therapy management agreement. The
 230 board may, in its discretion, grant an exception to this limitation on a case by case
 231 basis to a pharmacist who does not possess the academic degree required by this
 232 Section upon the affirmative recommendation and advice of the advisory
 233 committee that the pharmacist possesses the equivalent or other acceptable
 234 advanced training in the area of practice covered by the agreement.
- 235 f. The scope of the collaborative drug therapy management shall not include:
- 236 i. any patient of the physician for whom such physician has not prepared a
 237 patient specific, drug specific, disease or condition specific written
 238 protocol order set based on a face-to-face visit with the patient;
- 239 ii. ~~drug therapy management of more than one specific disease or condition.~~
 240 ~~Administration of a vaccine or smoking cessation therapy are excepted~~
 241 ~~from this provision.~~
- 242 iii. ~~drug therapy management of any patient by more than one registered~~
 243 ~~physician and one pharmacist;~~
- 244 iv. ~~any patient under the age of 18 years of age. Administration of a vaccine~~
 245 ~~or smoking cessation therapy are excepted from this provision.~~
- 246 v. ~~pregnant or nursing mothers;~~
- 247 vi. initiation or discontinuance of drug therapy by a pharmacist, except as
 248 specified in the written protocol order set;
- 249 vii. the management of controlled substances or drugs of concern; or
- 250 viii. substitution of a drug prescribed by a physician without the explicit
 251 written consent of such physician.

2. Informed Consent

- 253 a. A pharmacist shall not engage in collaborative drug therapy management of a
 254 patient without the patient's written informed consent.
- 255 b. In addition to the requirements provided by law for obtaining a patient's informed
 256 consent, each patient who is subject to a collaborative drug therapy management
 257 ~~agreement~~ shall be:
- 258 i. informed of the collaborative nature of drug therapy management for the
 259 patient's specific medical disease or condition and provided instructions
 260 and contact information for follow-up visits with the pharmacist and
 261 physician;
- 262 ii. informed he may decline to participate in a collaborative drug therapy
 263 management practice and may withdraw at any time without terminating
 264 the physician-patient or pharmacist-patient relationship; and
- 265 iii. provided written disclosure of any contractual or financial arrangement
 266 with any other party that may impact one of the party's decision to
 267 participate in the agreement.
- 268 c. All services provided ~~pursuant to a collaborative drug therapy management~~
 269 ~~agreement shall be consistent with the agreement and~~ shall be performed in a
 270 setting which insures patient privacy and confidentiality.

3. ~~Collaborative Drug Therapy Management Agreement~~

- 272 a. ~~A collaborative drug therapy management agreement shall, at a minimum, include:~~
- 273 i. ~~the name, professional license number, address or addresses,~~
 274 ~~telephone/cell phone number, e-mail address, and emergency contact~~
 275 ~~information for the pharmacist and physician, and the date of signing and~~
 276 ~~termination of the agreement;~~
- 277 ii. ~~a description of the manner and circumstances under which the~~
 278 ~~pharmacist and physician shall engage in collaborative drug therapy~~
 279 ~~management;~~
- 280 iii. ~~the condition or disease to be managed;~~
- 281 iv. ~~the specific drug or drugs to be utilized for such condition or disease;~~

- 282 v. ~~the drug therapy management activities, as defined in this Section, to be~~
 283 ~~performed by the pharmacist as authorized by the physician;~~
 284 vi. ~~the procedure to be followed by the parties for drug therapy management~~
 285 ~~and a plan of accountability defining the respective responsibilities of the~~
 286 ~~pharmacist and physician;~~
 287 vii. ~~a plan for reporting and documenting drug therapy management activities~~
 288 ~~in the pharmacy and medical records and schedule by which such are to~~
 289 ~~take place. A pharmacist shall submit a report to the collaborating~~
 290 ~~physician at least every 30 days, or more frequently if warranted by~~
 291 ~~clinical conditions, regarding the status of a patient's collaborative drug~~
 292 ~~therapy management, with such report made a part of the pharmacy~~
 293 ~~record for such patient;~~
 294 viii. ~~a plan for record keeping, record sharing, and record storage. The~~
 295 ~~agreement shall acknowledge all collaborative drug therapy management~~
 296 ~~records shall be treated as and governed by the laws applicable to~~
 297 ~~physician medical records;~~
 298 ix. ~~acknowledgement each patient subject to the agreement shall be notified~~
 299 ~~that a collaborative drug therapy management agreement exists, describes~~
 300 ~~the procedures for obtaining informed consent of such patient, and the~~
 301 ~~plan to address patient needs when both the pharmacist and physician are~~
 302 ~~absent from the practice setting; and~~
 303 x. ~~the procedure and schedule for reviewing and assessing the quality of~~
 304 ~~care provided to each patient subject to collaborative drug therapy~~
 305 ~~management under written protocol.~~
 306 b. ~~In the event the physician authorizes the pharmacist to order, evaluate, and apply~~
 307 ~~the results of a laboratory test or tests directly related to disease specific drug~~
 308 ~~therapy being managed under written protocol, the agreement shall identify the~~
 309 ~~specific test or tests and describe the plan for securing such testing.~~
 310 c. ~~The agreement shall affirm that:~~
 311 i. ~~collaborative drug therapy management shall be in conformity with~~
 312 ~~generally accepted standards of care for treatment of a patient's specific~~
 313 ~~disease or condition;~~
 314 ii. ~~all services provided pursuant to a collaborative drug therapy~~
 315 ~~management shall be consistent with the agreement and performed in a~~
 316 ~~setting that insures patient privacy and confidentiality; and~~
 317 iii. ~~a copy of the agreement shall be maintained on-site by the respective~~
 318 ~~parties.~~
 319 d. ~~The agreement may include the identity of one back up pharmacist possessing the~~
 320 ~~qualifications for collaborative drug therapy management required by this Section;~~
 321 ~~who shall serve in the absence of the registered pharmacist to the agreement. The~~
 322 ~~identifying information specified in this Section shall be provided for such~~
 323 ~~pharmacist, along with an acknowledgement of responsibility to adhere to the~~
 324 ~~same obligations and commitments imposed on the registered pharmacist to the~~
 325 ~~agreement, as evidenced by a dated signature.~~
 326 e. ~~An agreement is valid for a period of time not to exceed one year. A collaborating~~
 327 ~~pharmacist shall insure that a collaborative drug therapy management agreement is~~
 328 ~~annually reviewed, updated as appropriate, and signed by the pharmacist and~~
 329 ~~physician.~~
 330 f. ~~Each registered pharmacist is responsible for updating the board within 10 days in~~
 331 ~~the event any of the information required and submitted in accordance with this~~
 332 ~~Section changes after the board has approved the agreement.~~
 333 4. ~~Written Protocols~~ Order Sets
 334 a. ~~A separate protocol~~ order set shall be written for each patient to be managed by
 335 collaborative drug therapy management. A copy of each ~~written protocol~~ order set
 336 shall be:
 337 i. provided to the collaborating physician and pharmacist; and
 338 ii. made part of the patient's pharmacy record. ~~and~~

- 395 directed or required by the Louisiana Department of Health and
 396 Hospitals; and
- 397 vi. ~~confirmation the physician shall be promptly available for consultation~~
 398 ~~regarding contraindications and adverse reactions in said physician's~~
 399 ~~patient.~~
- 400 c. ~~This Section shall not prevent or restrict the Louisiana Department of Health and~~
 401 ~~Hospitals, Office of Public Health, or any other governmental entity of this state~~
 402 ~~from administering vaccines under the authority of other laws of this state.~~
- 403 6. ~~Additional Refills. Whether or not and the extent to which a collaborating physician may~~
 404 ~~authorize a collaborating pharmacist to dispense up to a single seven day supply of a single~~
 405 ~~drug for a single patient utilized for disease specific drug therapy after all refills authorized~~
 406 ~~for such physician's patient have been dispensed, shall be specifically included in the~~
 407 ~~collaborative drug therapy management agreement with such pharmacist, as well as the~~
 408 ~~written protocol applicable to a specific patient.~~
- 409 7. Reporting Obligations and Responsibilities
- 410 a. A pharmacist engaged in collaborative drug therapy management shall ~~notify the~~
 411 ~~board, in writing, within 10 days of the occurrence or discovery of: report~~
 412 ~~annually, as a condition to the renewal of his registration, whether or not and the~~
 413 ~~extent to which the pharmacist is engaged in collaborative drug therapy~~
 414 ~~management and such other information as the board may request; and~~
 415 i. ~~the death of a patient which was, in the pharmacist's opinion, directly~~
 416 ~~related to drug therapy management;~~
 417 ii. ~~complications or errors which are, in the pharmacist's opinion, directly~~
 418 ~~related to drug therapy management;~~
 419 iii. ~~a pharmacist's termination of a collaborative drug therapy management~~
 420 ~~agreement with a physician and applicable reasons;~~
 421 iv. ~~a physician's termination of a collaborative drug therapy management~~
 422 ~~agreement with a pharmacist and applicable reasons;~~
 423 v. ~~a patient's election to withdraw from participation in collaborative drug~~
 424 ~~therapy management and applicable reasons;~~
 425 vi. ~~his or a physician's failure or refusal to abide by the terms, conditions, or~~
 426 ~~restrictions of a collaborative drug therapy management agreement or~~
 427 ~~written protocol and applicable reasons;~~
 428 vii. ~~the pharmacist's retirement or withdrawal from active practice in this~~
 429 ~~state or relocation to another state to engage in pharmacy practice; or~~
 430 viii. ~~the revocation, suspension, or other restriction imposed on a physician's~~
 431 ~~license which would prohibit the physician from entering into a~~
 432 ~~collaborative drug therapy management agreement.~~
- 433 b. A pharmacist engaged in collaborative drug therapy management shall comply
 434 with reasonable requests by the board for personal appearances or information
 435 relative to the functions, activities, and performance of a pharmacist or physician
 436 engaged in collaborative drug therapy management.
- 437 8. Records
- 438 a. The following information shall be included in the pharmacy's record of a patient
 439 subject to collaborative drug therapy management:
- 440 i. the prescription or order implementing collaborative drug therapy
 441 management;
- 442 ii. the ~~written protocol~~ order set applicable to the patient evidencing
 443 documentation of the physician's annual review;
- 444 iii. documentation of all activities performed by the pharmacist;
- 445 iv. consultations and status reports by and between the pharmacist and
 446 physician; and
- 447 v. documentation of the patient's informed consent to collaborative drug
 448 therapy management.
- 449 b. A pharmacist registered to engage in collaborative drug therapy management shall
 450 maintain and produce, upon inspection conducted by or at the request of a
 451 representative of the board, a copy of any ~~or all collaborative drug therapy~~

452 ~~management agreements, amendments thereto, applicable written protocols~~ order
453 sets and such other records or documentation as may be requested by the board to
454 assess a pharmacist's compliance with requirements of this Section, the Pharmacy
455 Practice Act, or other applicable board rules.

456 E. Sanctions

- 457 1. Action against Registration. For noncompliance with any of the provisions of this Section,
458 the board may, in addition to or in lieu of administrative proceedings against a pharmacist's
459 license, suspend or revoke a pharmacist's registration to engage in collaborative drug therapy
460 management, or may impose such terms, conditions, or restrictions thereon as the board may
461 deem necessary or appropriate.
- 462 2. Action against Pharmacist License. Any violation or failure to comply with the provisions of
463 this Section shall be deemed a violation of R.S. 37:1241.A.1, as well as a violation of any
464 other applicable provisions of R.S. 37:1241.A, providing cause for the board to take any of
465 the actions permitted in R.S. 37:1241.A against the pharmacist's license.
- 466 3. Unauthorized Practice. Nothing in this Section shall be construed as authorizing a pharmacist
467 to issue prescriptions, exercise independent medical judgment, render diagnoses, provide
468 treatment, assume independent responsibility for patient care, or otherwise engage in the
469 practice of medicine as defined in the Louisiana Medical Practice Act. Any person who
470 engages in such activities, in the absence of medical licensure issued by the Louisiana State
471 Board of Medical Examiners, shall be engaged in the unauthorized practice of medicine and
472 subject to the penalties prescribed by the Louisiana Medical Practice Act.

473

474 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1164(37)(b)(i).

475 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1125
476 (June 2007), amended LR

477